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Tuberculosis (TB) is a re-emerging disease and is caused by Mycobacterium tuberculosis (M.
tuberculosis). TB is currently one of the leading causes of morbidity and mortality, world-
wide. The only available vaccine against TB infection, Bacillus CalmetteeGuerin (BCG), fails
to adequately protect against reactivation of latent infections in adults. Furthermore,
recently developed subunit vaccines, which are in various stages of clinical trials, are all
prophylactic vaccines based on proteins expressed in replicating stage of M. tuberculosis
and they are not preventive of reactivation of latent TB infection. Thus, an appropriate
subunit post-exposure vaccine needs to be developed to control all forms of TB infection.
To produce a multi-stage subunit vaccine, scientists should combine the early secreted M.
tuberculosis antigens with latency antigens. For this purpose, some latency proteins are
known which could be important antigens in the production of specific humoral and
cellular immune responses in latent M. tuberculosis infected individuals. Several studies
have evaluated the immunogenicity of these proteins in improving the TB vaccines. The
present study is a comprehensive review of several studies on the role of the latency an-
tigens in the development of TB vaccines. Overall, the studies indicate that the latency-
associated antigens including the resuscitation-promoting factors, the Dormancy of sur-
vival regulon (DosR) proteins and the starvation stimulant proteins are potential candi-
dates for the development of subunit vaccines against TB infection.
© 2019 Published by Elsevier B.V. on behalf of Tuberculosis Association of India.; Fax: þ98 5138409612.
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Tuberculosis (TB), caused by Mycobacterium tuberculosis (M.
tuberculosis), is a re-emerging infectious disease and is one of
the leading causes of morbidity and mortality in many coun-
tries, especially in developing countries.1 According to the
latest report by theWorld Health Organization (WHO) in 2018,
about 10 million people had TB, which led to1.3 million
deaths. This state is further exacerbated due toTB/HIV co-
infection, multidrug-resistant (MDR) M. tuberculosis strains
and the appearance of extremely drug-resistant (XDR) M.
tuberculosis strains.2 Currently, vaccination is one of the most
effective approaches in prevention and control TB infection.
The TB vaccine, Bacillus CalmetteeGuerin (BCG), is the only
available approved vaccine against TB and has been widely
used in many countries for decades.3 BCG provides highly
variable efficacies against adult pulmonary TB infectionwith a
range of 0e80% protection. BCG also fails to adequately pro-
tect against reactivation of latent infections in adults.
Furthermore, the current vaccine suffers from inability to
eliminate latent TB infection, and loss of efficacy over time
and in immune compromised patients.4,5 One of the impor-
tant differences between M. tuberculosis and other pathogens
is the survival of bacteria in an intracellular habitat in the
human cells for decades and its establishment as a latent
infection. About one-third of the global population has latent
TB infection and about 5e10% of them will eventually prog-
ress active TB infection whenever their immune status sup-
presses. Patients with latent TB infection are the major
reservoir of adult TB infection.6,7 Most TB vaccines that
recently entered different phases of clinical trials were based
on proteins expressed in replicating stages. Such TB vaccines
can prevent active TB infection (prophylactic vaccine) but not
latent TB infection.6 Thus, a more effective subunit post-
exposure vaccine is needed to control all forms of TB infec-
tion in adults, especially latent infection. To produce a multi-
stage subunit vaccine, researchers should combine early
secreted antigens such as Ag85B with M. tuberculosis latency
antigens such as HspX.6 Recently, some multi-stage subunit
vaccines i.e. Hybrid 56 þ IC31 and ID93þGLA-SE, containing
dormancy antigens, have entered clinical trials.8,9 Latency-
associated antigens have shown to elicit appropriate and
strong immune and protective responses.10 These antigens
include: 1) the Dormancy of survival regulon (DosR) proteins
which are responsible for adaptation to hypoxia. These
constitute the latency expressing proteins; 2) nutrient star-
vation proteins; and 3) enduring hypoxic response (EHR) genes
which comprise many genes of the DosR regulon.11,12
Recently, scientists have used several M. tuberculosis proteins
homologous to the resuscitation-promoting factor (rpfa-A-E)
of Micrococcus luteus. These proteins are involved in resusci-
tation and reactivation of dormant TB infection and to control
reactivated M. tuberculosis. These proteins lead to specific
humoral and cellular immune responses in latently M. tuber-
culosis infected individuals. Thus,M. tuberculosis resuscitation-
promoting factors proteins (Rpf), particularly RpfB which
memory T-cells able to respond to them can be used as anti-
gens for novel TB subunit vaccines.13,14 DosR-regulated pro-
tein HspX is an important antigen that leads to specificPlease cite this article as: Yousefi Avarvand A et al., The roles of laten
Tuberculosis, https://doi.org/10.1016/j.ijtb.2019.04.012humoral and cellular immune responses in latently M. tuber-
culosis infected individuals.15 This protein is known to be
targeted by CD4þ and CD8þ T cells. On the other hand, several
of other latency antigens such as RV2628c, RV1813, RV2660,
RV0072, RV1737 and RV2031c have been shown to induce
strong Th1-mediated immune responses.16,17 Some previous
studies have suggested that latency-associated antigens in all
kinds of TB vaccines can induce strong humoral and/or
cellular Th1-mediated immune responses.16e18 Therefore, it
could be hypothesized that a heterologous prime boost vac-
cine, including a combination of dormant antigens to induce a
specific immune response, is more protective than the ho-
mologous prime boost vaccine. The present review article
focuses on dormancy-related antigens of M. tuberculosis as
potentially ideal candidates in the development of new vac-
cine against TB.2. Resuscitation-promoting factors
Resuscitation-promoting factors (Rpf) are proteins with
peptidoglycan-hydrolyzing activity and are vital for
mycobacterial virulence, especially for resuscitation from
dormancy. These proteins were first reported in M. luteus
as a secretory protein. Mutant M. tuberculosis strains with
a deficiency in Rpf show inability in replication, reac-
tivation and in resistance to stress probably due to
changes in their cell wall structure.19 There are five rpf
genes in the M. tuberculosis genome (rpfA-E) which are very
similar to those of Rpf from M. luteus.14 Rpf proteins are
potential targets for the host immune response. Rpf are
key virulence factors for M. tuberculosis and responses to
Rpf could be protective. These have been evaluated in
cellular experiments and mouse models.14 Previous
studies have demonstrated that RpfB and RpfE produce
protective immune responses in-vitro and are potential
candidates for the development of vaccine.20 RpfB and
RpfE induce the maturation of dendritic cells (DCs) and
these activated DCs polarize T-cell proliferation toward
Th1 phenotype. RpfE also induces Th17 development
which in addition to Th1 is needed for appropriate pro-
tection against M. tuberculosis.20,21 The immune responses
induced by Rpf antigens and their protective efficacy
against challenge with virulent M. tuberculosis have been
evaluated in animal models.22 Lee et al demonstrated that
when C57BL/6 mice were vaccinated intramuscularly with
RpfB using a plasmid DNA vector, it can elicit a significant
poly functional CD8þT cell responses in mice, suggesting
that RpfB DNA immunization may be protective against
TB infection.21 In another study RpfB and RpfD were re-
ported to be the most antigenic in the tested models. It
was also indicated that RpfB protein is the most immu-
nogenic antigen among the five Rpf proteins of M. tuber-
culosis, implying that Rpf proteins can be used as an
antigen in new TB vaccines.14 In conclusion, RpfB and
RpfE induce immune responses associated with resistance
to M. tuberculosis and provide some levels of protection in
animal models. Further human-based studies are needed
to evaluate if the observation could be replicated in
humans and whether Rpf should be considered ascy-associated antigens in tuberculosis vaccines, Indian Journal of
i n d i a n j o u r n a l o f t u b e r c u l o s i s x x x ( x x x x ) x x x 3antigens for development of a subunit vaccine against M.
tuberculosis.223. Dormancy of survival regulon (DosR)
A region in the genome of M. tuberculosis called DosR regulon
contains 50 latency-associated genes and is active during la-
tency. Most latency-associated antigens related to DosR reg-
ulon including Rv2031c, Rv2029c, Rv2628c, Rv1737c, Rv1733c
and Rv0081 were evaluated for their immunogenic charac-
teristics in different studies.16 This review summarizes the
possible role of DosR regulon proteins as effective candidates
for development of subunit vaccines against TB infection.
3.1. Rv2031c (gene name: hspX; gene length: 435 bp;
144 amino acids)
An important antigen from the DosR regulon is a stress
protein induced by hypoxia and nutrient scarcity is called
heat-shock protein X ora-crystallin ((14 kDa antigen)
(HSP16.3)).23 The expression of HspX protein is regulated by
DosR regulon in different environmental conditions.24 HspX
is associated with bacterial growth, escape from the host
immune system and prolonged bacterial survival in mac-
rophages during latent infections.25,26 One of the most
crucial immune responses against M. tuberculosis infection
is activation of T helper1 (Th1) and cytotoxic T (Tc) cells.
HspX strongly induces Th1 cytokines such as IFN-g (inter-
feron gamma) and TNF-a (tumor necrosis alpha) followed
by induction of cellular and humoral immune responses in
the latent phase of TB infection.27,28 Several studies have
shown the efficacy of HspX protein for the induction of
strong Th1-medited immune responses and its potential to
be a suitable antigen candidate for vaccination against TB
infection. As an example, in a study conducted by Yuan
et al, a DNA vaccine was constructed expressing a fusion
protein of M. tuberculosis antigens including Ag85B, Esat6
and HspX. After vaccination of mice with DNA vaccine, a
significant increase in antigen-specific IFN-g against HspX
antigen and higher levels of HspX specific T cell prolifera-
tion was observed, compared to vaccination with BCG.29
Geon et al evaluated immune responses against Ag85A
and HspX antigens in the mice model. Ag85A and HspX
increased the level of IFN-g responses. Also, after mice
challenge with M. tuberculosis, HspX subunit vaccine
induced significant protective immunity.30 In another study,
Yuan et al developed a new recombinant BCG expressing
high levels of Ag85B and HspX. After vaccination of mice
with this vaccine, the immunization of new vaccine
compared to BCG. It was observed that the new vaccine
was able to protect mice against intranasal infection of M.
tuberculosis better than that of BCG.31 Similar results were
shown by Xin et al, Marongiu et al, de Sousa et al, Geluk et
al and Costa et al confirmed the immunogenicity of HspX
antigen.9,25,28,32,33 Several studies indicated that HspX pro-
tein either in combination with adjuvants or as encapsu-
lated with nanoparticles can strongly induce the immune
system. In a study conducted by Khademi et al, HspX an-
tigen was shown to efficiently induce mucosal and systemicPlease cite this article as: Yousefi Avarvand A et al., The roles of laten
Tuberculosis, https://doi.org/10.1016/j.ijtb.2019.04.012immune responses in BALB/c mice, when combined with a
replicating bacilli antigen, as multi-stage subunit vaccine
(HspX/EsxS-fused protein), alone or as encapsulated in
PLGA and PLGA:DDA hybrid nanoparticles.34 Additionally,
they showed that adding DOTAP and MPLA adjuvants to
HspX/EsxS-fused protein could enhance immune responses
after subcutaneous and nasal immunization of BALB/c
mice.34,35 In another study by Mansury et al, HspX protein
in combination with PPE44 and EsxV proteins were encap-
sulated into DOTAP liposome. They showed that this
formulation was able to induce a strong Th1-mediated
response.36 Amini et al reported a multi-component vac-
cine containing HspX in combination with PPE44 and EsxV
antigens adsorbed on calcium phosphate nanoparticles
could induce strong cellular immunity in an animal
model.37 Niu et al developed a new multi-sage subunit
vaccine against TB infection containing ESAT6-Ag85B-
MPT64-Mtb8.4-HspX antigens along with two adjuvants,
DDA and Poly I:C. They showed that this new vaccine could
induce a stronger immunity compared to traditional BCG
vaccine.38
3.2. Rv2029c (gene name: pfkB; gene length: 1020 bp;
339 amino acids)
M. tuberculosis pfkB gene encodes a 35 kDa-latency protein
with kinase and phosphotransferase activity. This M. tuber-
culosis latency antigen is DosR-regulon-encoded antigen and
as a probable 6-phosphofructokinase (pfkB) is involved in
glycolysis: converts sugar-1-P to sugar-1, 6-P.39 The immuno-
genicity of this latency protein was evaluated in different
studies. Arroyo et al reported that M. tuberculosis latency an-
tigen Rv2029c was able to induce higher immune responses of
T cells (CD4þ or CD8þ) producing IFN-g and TNF-a in latently
M. tuberculosis infected individuals.39 The immunogenicity
profile of Rv2029c antigen has also been investigated by
Mensah and colleagues.40 They reported that latency antigen
Rv2029c was able to induce higher levels of IFN-g, Granzyme
B, TNF-a and IL-17 and also low levels of IL-10 and sIL-2R-a in
peripheral blood mononuclear cell.
3.3. RV2628c (gene name: Rv2628; gene length: 363 bp;
120 amino acids)
M. tuberculosis Rv2628 gene encodes a 13 kDa-latency antigen
RV2628c protein with unknown function. It was reported that
thisM. tuberculosis DosR-regulon-encoded antigen can induce
strong long-term IFN-g responses. As an example, Goletti et al
study showed that this latency antigen may induce immune-
mediated protection against TB infection.17 Similar results
DosR-regulon-encoded protein Rv2029c, Mensah and col-
leagues were reported for DosR-regulon-encoded protein
Rv2628.40
3.4. Rv1737c(gene name: narK2; gene length: 1188 bp;
395 amino acids)
The protein expressed by this gene i.e. nitrate/nitrite trans-
porter NarK2 is involved in the excretion of nitrite across the
membrane. Arroyo et al assessed the DosR antigens Rv1737ccy-associated antigens in tuberculosis vaccines, Indian Journal of
i n d i a n j o u r n a l o f t u b e r c u l o s i s x x x ( x x x x ) x x x4immunogenicity and reported that it is capable of promoting T
cells responses.39
3.5. Rv1733c (gene name: Rv1733c; gene length: 633 bp;
210 amino acids)
Rv1733c is a probable conserved transmembrane proteinwith
unknown function. It was indicated as a potent inducer of T
cell antigen in bioinformatics analysis.16 However, this DosR-
regulon-encoded antigen is also known to be immunogenic
in vitro experiments conducted by Mensah et al, Kassa et al and
Commander et al40e42
3.6. Rv0081 (gene name: Rv0081; gene length: 345 bp;
114 amino acid)
Twelve kDaRv0081 antigens belong to the latency-associated
antigens and is encoded by DosR regulon.16 This M. tubercu-
losis sDosR-regulon-encoded antigen is a probable transcrip-
tional regulatory protein and involved in transcriptional
mechanism. Kassa et al reports on the immune response
against Rv0081 antigen confirmed Rv0081 antigen as a potent
immunogenic antigen.414. The starvation regulon
4.1. Rv2660c (gene name: Rv2660c; gene length: 228 bp;
75 amino acid)
A collection of genes including Rv2660 and Rv2659 called the
starvation regulon and expressed in response to nutrient
deprivation by M. tuberculosis.16 Govender et al suggested that
the starvation stimulon gene product Rv2660 is a suitable
antigenic candidate in a post-infection vaccine against TB
infection. They showed that Rv2660 induced IFN-g production
in latently M. tuberculosis infected individuals.435. Conclusion
In all literature reviewed in the current study, it has been
shown that the latency-associated antigens including
resuscitation-promoting factors, the DosR regulon encoded
antigens and the starvation regulon encoded antigens can
stimulate cellular immune responses against latent TB infec-
tion. Therefore, they could be potential candidate antigens for
immunization as a prophylactic vaccine against the latent
stage of TB infection and could prevent the reactivation of
latent infection.r e f e r e n c e s
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